DEPO-TESTOSTERONE INJ 100MG/ML SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

TESTOSTERONE CYPIONATE

可用日期:

PFIZER CANADA ULC

ATC代码:

G03BA03

INN（国际名称）:

TESTOSTERONE

剂量:

100MG

药物剂型:

SOLUTION

组成:

TESTOSTERONE CYPIONATE 100MG

给药途径:

INTRAMUSCULAR

每包单位数:

10ML

处方类型:

Schedule G (CDSA IV)

治疗领域:

ANDROGENS

產品總結:

Active ingredient group (AIG) number: 0106401001; AHFS:

授权状态:

APPROVED

授权日期:

2001-06-04

产品特点

_ _
_DEPO-TESTOSTERONE Product Monograph _
_ _
_Page 1 of 20_
PRODUCT MONOGRAPH
DEPO-TESTOSTERONE
testosterone cypionate injection
100 mg/mL sterile solution
USP
Androgens
Pfizer Canada Inc.
17, 300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Revision:
July 12, 2018
Submission Control No: 217239
©
Pfizer Canada Inc., 2018
_ _
_DEPO-TESTOSTERONE Product Monograph _
_Page 2 of 20 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFO